Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer’s Hopes For Ibrance In Adjuvant Breast Cancer Fall With PALLAS

Executive Summary

Ibrance (palbociclib) is unlikely to succeed in the adjuvant trial, the data safety monitoring board concluded. Pfizer has another adjuvant trial due later this year. 

You may also be interested in...



Lilly’s Early Bird Verzenio Goes After Up To S4bn Worm With Early Breast Cancer Nod

Given the requirement for patients to have a Ki-67 score of at least 20%, the challenge now is to alter physicians’ thinking around Ki-67 testing, execs told Scrip.

Pfizer Ibrance Hopes Dashed In Early-Stage Breast Cancer

Data from the PENELOPE-B study in high-risk early breast cancer patients show no separation from placebo, compounding the earlier failure of the PALLAS trial in low- and high-risk patients.

Stockwatch: MonarchE And Tug-Of-War Drug Development

With Lilly, Pfizer and Novartis duking it out for early-stage breast cancer patients, how many drugs for the same indication is too many?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142326

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel